Chemistry:Dasolampanel
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C17H20ClN5O3 |
| Molar mass | 377.83 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Dasolampanel (INN, USAN, code name NGX-426) is an orally bioavailable analog of tezampanel and thereby competitive antagonist of the AMPA and kainate receptors which was under development by Raptor Pharmaceuticals/Torrey Pines Therapeutics for the treatment of chronic pain conditions including neuropathic pain and migraine.[1] It was developed as a follow-on compound to tezampanel, as tezampanel is not bioavailable orally and must be administered by intravenous injection,[2][3] but ultimately neither drug was ever marketed.
See also
References
- ↑ Encyclopedia of Psychopharmacology. Springer Science & Business Media. 31 July 2010. pp. 514–. ISBN 978-3-540-68698-9. https://books.google.com/books?id=qoyYobgX0uwC&pg=PA514.
- ↑ Innovative Drug Development for Headache Disorders. Oxford University Press. 21 August 2008. pp. 188–. ISBN 978-0-19-955276-4. https://books.google.com/books?id=h72Zdp1gtXYC&pg=PA188.
- ↑ Kelley's Textbook of Rheumatology: Expert Consult Premium Edition: Enhanced Online Features. Elsevier Health Sciences. 31 August 2012. pp. 1031–. ISBN 978-1-4557-3767-3. https://books.google.com/books?id=R4ATV-17cv8C&pg=PA1031.
 |  |
